YHO-13177 is a potent and specific inhibitor of breast cancer resistance protein (BCRP/ABCG2).
YHO-13177 is a potent and specific inhibitor of breast cancer resistance protein (BCRP/ABCG2).
YHO-13177 is a potent and specific inhibitor of breast cancer resistance protein (BCRP/ABCG2).
YHO-13177 is a potent and specific inhibitor of breast cancer resistance protein (BCRP/ABCG2).
YK 3-237 is a boronic acid chalcone analog of combretastatin a4 (CA-4) and a SIRT1 activator that targets mutant p53. YK 3-237 can reduce the acetylation of mutant p53 protein by activating the SIRT1 enzyme, resulting in a significant decrease in the level of mutant p53 protein. YK-3-237 showed antiproliferative activity against tumor cells containing...
YK 3-237 is a boronic acid chalcone analog of combretastatin a4 (CA-4) and a SIRT1 activator that targets mutant p53. YK 3-237 can reduce the acetylation of mutant p53 protein by activating the SIRT1 enzyme, resulting in a significant decrease in the level of mutant p53 protein. YK-3-237 showed antiproliferative activity against tumor cells containing...
YK 3-237 is a boronic acid chalcone analog of combretastatin a4 (CA-4) and a SIRT1 activator that targets mutant p53. YK 3-237 can reduce the acetylation of mutant p53 protein by activating the SIRT1 enzyme, resulting in a significant decrease in the level of mutant p53 protein. YK-3-237 showed antiproliferative activity against tumor cells containing...
YK 3-237 is a boronic acid chalcone analog of combretastatin a4 (CA-4) and a SIRT1 activator that targets mutant p53. YK 3-237 can reduce the acetylation of mutant p53 protein by activating the SIRT1 enzyme, resulting in a significant decrease in the level of mutant p53 protein. YK-3-237 showed antiproliferative activity against tumor cells containing...
YK-4-279 is a potent inhibitor of ETV1 and inhibits both the primary tumor growth and metastasis of fusion positive prostate cancer xenografts.
YK-4-279 is a potent inhibitor of ETV1 and inhibits both the primary tumor growth and metastasis of fusion positive prostate cancer xenografts.
YK-4-279 is a potent inhibitor of ETV1 and inhibits both the primary tumor growth and metastasis of fusion positive prostate cancer xenografts.